Finoriq

Finoriq research workspace

Revolution Medicines, Inc. (RVMD) Institutional Holdings & 13F Ownership

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel. Review RVMD institutional holders, 13F ownership, and position changes on Finoriq.

Company Snapshot

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Company
Revolution Medicines, Inc. (RVMD)
Ticker
RVMD
Market Cap
$38.7B
Latest Price
$181.88
Industry
Biotech & Pharma

Open insider transactions

Revolution Medicines, Inc. (RVMD) Top Institutional Holders

Top current 13F holders indexed for Revolution Medicines, Inc. (RVMD). Latest period 2026-03-31.

RankInvestorValuePortfolioFiling
1Stanley DruckenmillerCIK 0001536411$30.7M0.91%Filing2026-05-15
2Ken FisherCIK 0000850529$21M0.01%Filing2026-05-05
3Joel GreenblattCIK 0001510387$12.2M0.04%Filing2026-05-15
4Ron BaronCIK 0001017918$243,1250.0%Filing2026-05-15

Live data loads in the app

This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.